Effectiveness and Safety of Nirmatrelvir-Ritonavir in Hospitalized Patients with COVID-19: A Two-center Cohort Study
Rattachement africain : sa, us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Abstract Background: On May 25, 2023, the antiviral medication nirmatrelvir-ritonavir received complete FDA authorization, making it the first oral antiviral to treat mild-to-moderate COVID-19 in high-risk patients for progression to severe COVID-19. While the effect of nirmatrelvir-ritonavir is endorsed in non-hospitalized patients, its effectiveness in hospitalized patients remains uncertain. This study aimed to investigate the effectiveness of nirmatrelvir-ritonavir in treating COVID-19 among hospitalized patients. Materials and Methods: A retrospective observational cohort study involving two centers was carried out in the Makkah and Jazan regions of Saudi Arabia from January 2023 to August 2023. The study included adult patients hospitalized who were diagnosed with COVID-19. Patients were classified into two sub-cohorts based on their nirmatrelvir-ritonavir treatment status within five days following COVID-19 detection. The primary outcome of the study was the in-hospital mortality. The secondary outcomes included ICU admissions, mechanical ventilation needs, acute kidney injury (AKI), and liver injury during hospital stay. Results: A total of 234 patients admitted with COVID-19 were screened, while 74 were included in the study. The in-hospital mortality showed no significant difference between the groups in the crude analysis (10% vs. 14%; P = 0.64). This finding was consistent in the regression analysis after adjusting for potential confounders (aOR = 2.95; 95% CI: 0.45–19.52; P = 0.26). The nirmatrelvir-ritonavir patients (treatment group) had higher odds of COVID-19 complications; however, this difference was not statistically significant (aOR=2.62; 95% CI:0.44–15.76; P = 0.29). Admission to the ICU was lower in the treatment group but did not achieve a statistical difference. There were no significant differences in other complications during hospitalization between the two groups. Conclusion: This study highlights that nirmatrelvir-ritonavir use in hospitalized COVID-19 patients did not result in improved hospital mortality or reduction in COVID-19 related complications.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Effectiveness and Safety of Nirmatrelvir-Ritonavir in Hospitalized Patients with COVID-19: A Two-center Cohort Study
- Date Crossref
- 01/04/2025
- Éditeur
- Ovid Technologies (Wolters Kluwer Health)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
King Saud Medical City pays non établi dans la noticeÉtablissement de santé
-
King Saud University Sleep Medicine Fellowship pays non établi dans la noticeUniversité ou école supérieure
-
King Abdullah Medical City pays non établi dans la noticeÉtablissement de santé
-
King Saud bin Abdulaziz University for Health Sciences pays non établi dans la noticeUniversité ou école supérieure
-
King Abdulaziz Medical City pays non établi dans la noticeÉtablissement de santé
-
King Abdullah International Medical Research Center pays non établi dans la noticeStructure de recherche
-
King Abdulaziz University Pharmaceutical Care Services pays non établi dans la noticeUniversité ou école supérieure
-
National Guard Health Affairs pays non établi dans la noticeÉtablissement de santé
-
Saad Specialist Hospital pays non établi dans la noticeÉtablissement de santé
-
King Faisal University pays non établi dans la noticeUniversité ou école supérieure
-
King Fahad Central Hospital pays non établi dans la noticeÉtablissement de santé
-
University of Pittsburgh Department of Cardiothoracic Surgery pays non établi dans la noticeUniversité ou école supérieure
King Saud Medical City, Sleep Medicine Fellowship — King Saud University et King Abdullah Medical City, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.